The present invention relates to a process for preparation of Batefenterol of Formula (I) or pharmaceutically acceptable salts thereof, and the process for the preparation of the chiral intermediate compounds including compound of Formula (VII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds of Formula (VII), followed by preparation of Batefenterol from the intermediate compounds of Formula (VII) via intermediate compounds of Formula (X) and Formula (XI); or via intermediate compounds of Formula (IX) and Formula (XI); or via intermediate compounds of Formula (VII) and Formula (XI); or via intermediate compounds of the Formula (XV) and Formula (XVI); or via intermediate compounds of the Formula (XIX) and Formula (XVI). The process is cost effective and gives higher yield and better purity. The process of the present invention does not use hypertoxic materials and the final compound (I) prepared by the process is highly efficient and possess excellent powdery nature.
The present invention relates to a process for preparation of Batefenterol of Formula (I) or pharmaceutically acceptable salts thereof, and the process for the preparation of the chiral intermediate compounds including compound of Formula (VII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds of Formula (VII), followed by preparation of Batefenterol from the intermediate compounds of Formula (VII) via intermediate compounds of Formula (X) and Formula (XI); or via intermediate compounds of Formula (IX) and Formula (XI); or via intermediate compounds of Formula (VII) and Formula (XI); or via intermediate compounds of the Formula (XV) and Formula (XVI); or via intermediate compounds of the Formula (XIX) and Formula (XVI). The process is cost effective and gives higher yield and better purity. The process of the present invention does not use hypertoxic materials and the final compound (I) prepared by the process is highly efficient and possess excellent powdery nature.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
2.
A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF
The present invention relates to a process for preparation of Navafenterol of Formula (I) and intermediate compounds of Formula (VII) and Formula (XIII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds of Formula (VII) and Formula (XIII) followed by preparation of Navafenterol from the compound of Formula (XIII) either by condensation with the compound of Formula (XVI); or via intermediates of the compound of Formula (XVIII) and compound of Formula (XV); or via intermediates of the compound of Formula (XI-a) and compound of Formula (XVI). The process uses simple raw materials and reagents. Further, the process is cost effective and gives higher yield and better purity.
The present invention relates to a process for preparation of Navafenterol of Formula (I) and intermediate compounds of Formula (VII) and Formula (XIII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds of Formula (VII) and Formula (XIII) followed by preparation of Navafenterol from the compound of Formula (XIII) either by condensation with the compound of Formula (XVI); or via intermediates of the compound of Formula (XVIII) and compound of Formula (XV); or via intermediates of the compound of Formula (XI-a) and compound of Formula (XVI). The process uses simple raw materials and reagents. Further, the process is cost effective and gives higher yield and better purity.
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
3.
A PROCESS FOR PREPARING ABEDITEROL AND INTERMEDIATES THEREOF
The present invention relates to a process for preparation of Abediterol of the Formula (I) or its pharmaceutically acceptable salts, and intermediate compounds including the compound of the Formula (VII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds followed by preparation of Abediterol from the intermediate compounds. The compound Abediterol having the formula I is synthesized by various routes from the intermediate compound of Formula (VII). The process is cost effective and gives higher yield and better purity. The process of the present invention uses simple raw materials and reagents; and does not use hypertoxic materials.
The present invention relates to a process for preparation of Abediterol of the Formula (I) or its pharmaceutically acceptable salts, and intermediate compounds including the compound of the Formula (VII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds followed by preparation of Abediterol from the intermediate compounds. The compound Abediterol having the formula I is synthesized by various routes from the intermediate compound of Formula (VII). The process is cost effective and gives higher yield and better purity. The process of the present invention uses simple raw materials and reagents; and does not use hypertoxic materials.
The present invention discloses a process for preparation of Batefenterol of Formula (I) or pharmaceutically acceptable salts thereof, and its intermediates by epoxidation. The process involves preparation of the intermediate compound of Formula (VII), followed by preparation of Batefenterol from the intermediate compound of Formula (VII) via intermediate compounds of Formulae (X) and (XI); or via intermediate compounds of Formulae (IX) and (XI); or via intermediate compounds of Formulae (VII) and (XI); or via intermediate compounds of the Formulae (XV) and (XVI); or via intermediate compounds of the Formulae (XIX) and (XVI). The process is cost effective and gives higher yield and better purity. The process does not use hypertoxic materials and yields compound (I) that is highly efficient and possess excellent powdery nature.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 11/00 - Drugs for disorders of the respiratory system
The present invention relates to a process for preparation of Abediterol of the Formula (I) or its pharmaceutically acceptable salts, and intermediate compounds including the compound of the Formula (VII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds followed by preparation of Abediterol from the intermediate compounds. The compound Abediterol having the formula I is synthesized by various routes from the intermediate compound of Formula (VII). The process is cost effective and gives higher yield and better purity. The process of the present invention uses simple raw materials and reagents; and does not use hypertoxic materials.
C07C 217/10 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
C07C 215/30 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
C07C 217/26 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is further substituted by halogen atoms or by nitro or nitroso groups
6.
A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF
The present invention relates to a process for preparation of Navafenterol of Formula (I) and intermediate compounds of Formula (VII) and Formula (XIII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds of Formula (VII) and Formula (XIII) followed by preparation of Navafenterol from the compound of Formula (XIII) either by condensation with the compound of Formula (XVI); or via intermediates of the compound of Formula (XVIII) and compound of Formula (XV); or via intermediates of the compound of Formula (XI-a) and compound of Formula (XVI). The process uses simple raw materials and reagents. Further, the process is cost effective and gives higher yield and better purity.
C07C 17/00 - Preparation of halogenated hydrocarbons
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
7.
A PROCESS FOR THE PREPARATION OF UMECLIDINIUM BROMIDE AND INTERMEDIATES THEREOF
Provided herein is a process for the preparation of umeclidinium bromide and intermediates thereof, wherein pure form of umeclidinium bromide is achieved by a two step process under mild conditions.
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Provided herein are processes for preparation of glycopyrronium bromide comprising reaction of N-methylpyrrolidin-3-ol with compounds of Formula I or Formula II followed by additional steps.
Provided herein is a process for synthesis of tiotropium bromide wherein the coupling of scopine with 2, 2-dithienyl glycolate is achieved by a two step process under mild conditions.
Provided herein is a process for synthesis of aclidinium bromide and intermediates thereof, wherein the process for the preparation of aclidinium bromide increases the % yield of aclidinium bromide by about 70% to 90%.
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
11.
A PROCESS FOR PREPARING TIOTROPIUM BROMIDE AND INTERMEDIATES THEREOF
Provided herein is a process for synthesis of tiotropium bromide and a process for synthesis of scopine starting from a dimethyl tartarate compound. The synthetic sequence comprises a double Mannich reaction (Robinson-Schopf reaction).
patents
